Wordt geladen...
奥希替尼在非小细胞肺癌靶向治疗中的获得性耐药机制
While treating cancer, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) still faces inevitable drug resistance. Investigations into the mechanisms which foster resistance to EGFR-TKI has led to the discovery of novel biomarkers and drug targets, and in turn has enabled the devel...
Bewaard in:
| Gepubliceerd in: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
中国肺癌杂志编辑部
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7210090/ https://ncbi.nlm.nih.gov/pubmed/32316715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.103.02 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|